Drug intelligence / Profile preview

ZS-1004

Development stage: Preclinical
Lead developer: Genuine Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

ZS-1004 is an antibody-drug conjugate (ADC) developed by Bio Genuine for the treatment of prostate cancer. It is designed to target the prostate-specific membrane antigen (PSMA), a cell-surface protein that is significantly overexpressed in prostate cancer cells compared to normal tissues. Upon binding to PSMA, the ADC is internalized into the cell, where the cytotoxic payload is released to induce cell death. This targeted approach aims to enhance therapeutic efficacy while reducing the off-target effects typically associated with systemic chemotherapy.

Other names: ZS-1004-Bio Genuine-PSMA-ADCZS1004-Bio Genuine-PSMA-ADCZS 1004-Bio Genuine-PSMA-ADC

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on ZS-1004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZS-1004.

Explore the full profile